To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Depression In Breast Cancer Patients Linked To Lack Of Estrogen URL: http://www.pslgroup.com/dg/10D582.htm Doctor's Guide June 29, 1999
WASHINGTON, DC -- June 29, 1999 -- Breast cancer patients may face an increased risk of depression as a result of treatment that disrupts their bodies' supplies of estrogen, according to the results of a pilot study conducted at Massachusetts General Hospital, Boston. "Dysphoria, insomnia and hot flashes were almost universal in women whose breast cancer treatment induced estrogen deficiency," said Donna Greenberg, M.D., one of the authors of the study. "The rather abrupt change in estrogen adds to other adverse side effects of adjuvant chemotherapy and presents another difficulty for these patients." The researchers, led by Laura Sheingold Duffy, M.D., selected 21 breast cancer patients likely to develop estrogen deficiency. The scientists conducted interviews regularly for an average of 18 months after beginning treatment with chemotherapy and/or tamoxifen. Eight women (38 percent) developed major depression, most in the first six months of treatment. The patients included 15 women who had not yet experienced menopause at the time of diagnosis, 14 of whom showed signs of estrogen deficiency, developing hot flashes or no longer menstruating. Four of these patients became depressed. Among the six post-menopausal women, four became depressed and of these two had stopped taking estrogen replacement therapy at the time of diagnosis. Three of the eight patients with depression recovered fully after treatment with antidepressant medication; one treated with a low dose of antidepressant medication improved partially. One improved with psychotherapy and two with no treatment. One patient's depression did not improve over the 11 months she was followed, but she did choose not to seek treatment for depression. "Major depressive disorder, once identified, may be responsive to therapeutic psychopharmacologic treatment, despite the lack of estrogen," Greenberg said. "Even in those patients who did not develop major depressive disorder, the clinician's attention to and clarification of menopausal symptoms seemed to be an important therapeutic strategy." The results of the study appear in the July-August issue of Psychosomatics. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.